Skip to main content
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
Reply to N.-K.V. Cheung et al.
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.
Cytogenetic prognostication within medulloblastoma subgroups.
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.